|
46
|
| 127 |
Streptozocin
|
|
increases_quantity of
|
TNF
|
in serum; under hyperglycemic condition
|
| 131 |
Arjunolic acid
|
|
decreases_quantity of
|
TNF
|
in serum; in STZ treated rats
|
|
19133311
|
Diabetes mellitus, type I
|
|
78
|
| 256 |
Streptozocin
|
|
increases_expression of
|
TNF
|
in male mice
|
| 259 |
IL11
|
|
decreases_expression of
|
TNF
|
in multiple low doses of streptozotocin (MLD-STZ) treated male mice
|
|
15096655
|
Diabetes mellitus, type I
|
|
97
|
| 317 |
SOD1-p.G93A
|
|
increases_quantity of
|
TNF
|
in adult microglia; LPS stimulated
|
|
15378658
|
Amyotrophic lateral sclerosis
|
|
98
|
| 321 |
SOD1-p.G93A
|
|
increases_quantity of
|
TNF
|
in microglia cultures
|
|
19672969
|
Amyotrophic lateral sclerosis
|
|
203
|
| 806 |
TNF
|
|
increases_expression of
|
VEGFA
|
|
| 808 |
TNF
|
|
increases_expression of
|
EPOR
|
|
|
18413601
|
Amyotrophic lateral sclerosis
|
|
205
|
| 817 |
TNF
|
|
decreases_activity of
|
apoptotic process
|
|
| 826 |
TNF
|
|
decreases_activity of
|
abnormal calcium ion homeostasis
|
|
| 828 |
TNF
|
|
increases_expression of
|
CALB1
|
|
| 13713 |
TNF
|
|
increases_activity of
|
neurogenesis
|
|
|
7507336
|
Amyotrophic lateral sclerosis
|
|
341
|
| 1344 |
Metformin
|
|
decreases_expression of
|
TNF
|
in liver
|
|
10973319
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
357
|
| 1417 |
6-OHDA
|
|
increases_quantity of
|
TNF
|
in striatum and substantia nigra
|
| 1419 |
XENP345
|
|
decreases_activity of
|
TNF
|
|
| 1421 |
TNF
|
|
increases_activity of
|
neuron death
|
|
|
16971520
|
Parkinson disease
|
|
379
|
| 1555 |
SOD1-p.G93A
|
|
increases_quantity of
|
TNF
|
in SOD1(G93A) transgenic mice
|
| 1557 |
Lipophilic metal chelator DP-460
|
NOT |
increases_quantity of
|
TNF
|
in SOD1(G93A) transgenic mice
|
| 1558 |
Lipophilic metal chelator DP-109
|
NOT |
increases_quantity of
|
TNF
|
in SOD1(G93A) transgenic mice
|
|
17630988
|
Amyotrophic lateral sclerosis
|
|
385
|
| 1578 |
SOD1-p.G93A
|
|
increases_quantity of
|
TNF
|
in TLR2 stimulated murine microglial cell line BV-2; if SOD1(G93A) is overexpressed
|
| 1583 |
SOD1-p.G93A
|
NOT |
increases_expression of
|
TNF
|
in TLR2 stimulated murine microglial cell line BV-2; if SOD1(G93A) is overexpressed
|
| 1598 |
NCF1
|
|
affects_quantity of
|
TNF
|
in TLR2 stimulated murine microglial cell line BV-2; if SOD1(G93A) is overexpressed
|
| 1599 |
Acetylcysteine
|
|
decreases_quantity of
|
TNF
|
in TLR2 stimulated murine microglial cell line BV-2; if SOD1(G93A) is overexpressed
|
| 1605 |
ADAM10
|
|
affects_quantity of
|
TNF
|
in TLR2 stimulated murine microglial cell line BV-2; if SOD1(G93A) is overexpressed
|
| 1606 |
ADAM17
|
|
affects_quantity of
|
TNF
|
in TLR2 stimulated murine microglial cell line BV-2; if SOD1(G93A) is overexpressed
|
|
19091752
|
Amyotrophic lateral sclerosis
|
|
391
|
| 1608 |
SOD1-p.G93A
|
|
increases_quantity of
|
TNF
|
in spinal cord motor neurons; especially at stage 90-110 days
|
| 1626 |
SOD1-p.G93A
|
|
increases_expression of
|
TNF
|
in spinal cord motor neurons
|
| 1635 |
Thalidomide
|
|
decreases_expression of
|
TNF
|
in spinal cord motor neurons; in SOD1(G93A) transgenic mice
|
| 1636 |
Lenalidomide
|
|
decreases_expression of
|
TNF
|
in spinal cord motor neurons; in SOD1(G93A) transgenic mice
|
|
16510725
|
Amyotrophic lateral sclerosis
|
|
392
|
| 1619 |
SOD1-p.I113T
|
|
increases_quantity of
|
TNF
|
|
| 13501 |
Amyotrophic lateral sclerosis
|
|
increases_quantity of
|
TNF
|
|
|
16510725
|
Amyotrophic lateral sclerosis
|
|
396
|
| 1638 |
SOD1-p.G93A
|
|
increases_quantity of
|
TNF
|
in astrocytes; at 110 days of age
|
|
16510725
|
Amyotrophic lateral sclerosis
|
|
404
|
| 1732 |
SOD1-p.G93A
|
|
increases_expression of
|
TNF
|
in immortalized microglia
|
| 13527 |
ATP
|
|
increases_quantity of
|
TNF
|
in immortalized and primary microglia
|
| 13546 |
3'-O-(4-Benzoyl)benzoyl ATP
|
|
increases_quantity of
|
TNF
|
in immortalized and primary microglia
|
|
19734218
|
Amyotrophic lateral sclerosis
|
|
407
|
| 1793 |
GPAM
|
NOT |
affects_expression of
|
TNF
|
|
|
17389595
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
412
|
| 1820 |
TNF
|
|
increases_quantity of
|
CYBB
|
|
| 1821 |
TNF
|
|
increases_quantity of
|
PTGS2
|
|
| 1825 |
TNF
|
|
increases_activity of
|
motor neuron degeneration
|
|
| 8720 |
TNF
|
|
affects_activity of
|
I-kappaB kinase/NF-kappaB signaling
|
|
|
19477238
|
Amyotrophic lateral sclerosis
|
|
615
|
| 3249 |
TNF
|
|
increases_quantity of
|
KDR
|
|
| 3250 |
TNF
|
|
increases_expression of
|
NRP1
|
|
| 3251 |
TNF
|
NOT |
increases_expression of
|
FLT1
|
|
| 3267 |
TNF
|
|
increases_activity of
|
endothelial cell migration
|
|
| 3270 |
TNF
|
|
increases_activity of
|
wound healing
|
|
|
9705358
|
Amyotrophic lateral sclerosis
|
|
635
|
| 3385 |
TNF
|
|
affects_activity of
|
BCL2A1
|
in neuronal cells
|
| 3392 |
TNF
|
|
increases_activity of
|
neuron apoptotic process
|
|
|
16710367
|
Amyotrophic lateral sclerosis
|
|
647
|
| 3436 |
SOD1-mod
|
|
increases_expression of
|
TNF
|
|
| 3437 |
SOD1-p.G93A
|
|
increases_expression of
|
TNF
|
|
|
17394546
|
Amyotrophic lateral sclerosis
|
|
669
|
| 3573 |
MMP9
|
|
increases_quantity of
|
TNF
|
in spinal cord
|
|
17362932
|
Amyotrophic lateral sclerosis
|
|
682
|
| 3718 |
Status epilepticus
|
|
increases_expression of
|
TNF
|
in pilocarpine model
|
|
19055492
|
Status epilepticus
|
|
868
|
| 5191 |
SIRT1
|
NOT |
affects_quantity of
|
TNF
|
in blood; on high-fat diet, if SIRT1 is overexpressed
|
|
18840364
|
Diabetes mellitus, type II
Insulin resistance
|
|
904
|
| 5387 |
high-fat diet
|
|
increases_expression of
|
TNF
|
in liver
|
| 5389 |
SIRT1
|
NOT |
affects_expression of
|
TNF
|
in liver; in response to high-fat diet, if SIRT1 is overexpressed
|
|
18599449
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
947
|
| 5889 |
SIRT1
|
|
affects_quantity of
|
TNF
|
in liver; if SIRT1 is knocked out in liver
|
|
19356714
|
Diabetes mellitus, type II
Insulin resistance
Fatty liver disease, nonalcoholic
|
|
952
|
| 5860 |
Diabetes mellitus, type II
|
|
increases_quantity of
|
TNF
|
in blood vessels; Diabetes accelerates the appearance of cerebrovascular inflammation evidenced by increased levels of proinflammatory cytokines IL-6 and TNF-alpha
|
|
20385830
|
Alzheimer disease
|
|
1,026
|
| 6453 |
obesity, high-fat diet-induced
|
|
increases_expression of
|
TNF
|
|
| 6463 |
TNF
|
|
increases_expression of
|
PTPN1
|
in liver, in skeletal muscle, in adipose tissue, in arcuate nucleus; in FVB mice
|
|
18281274
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,032
|
| 6454 |
TNF
|
|
increases_expression of
|
PTPN1
|
in differentiated 3T3-L1 adipocytes, in H-4-II-E hepatoma cells, in HeLa cells
|
|
18281274
|
Diabetes mellitus, type II
Insulin resistance
|
|
1,092
|
| 7084 |
TNF
|
|
increases_activity of
|
TNFRSF1A
|
|
| 7089 |
TNF
|
|
decreases_expression of
|
INSR
|
in adipose tissue
|
| 7090 |
TNF
|
|
decreases_expression of
|
IRS1
|
in adipose tissue
|
| 7091 |
TNF
|
|
decreases_expression of
|
SLC2A4
|
in adipose tissue
|
| 7092 |
TNF
|
|
decreases_activity of
|
glucose import
|
in adipose tissue
|
| 7093 |
TNF
|
|
decreases_expression of
|
LIPE
|
in adipose tissue
|
| 7095 |
TNF
|
|
decreases_expression of
|
ACSL
|
in adipose tissue
|
| 7096 |
TNF
|
|
decreases_expression of
|
ADIPOQ
|
in adipose tissue
|
| 7097 |
TNF
|
|
decreases_expression of
|
CEBP
|
in adipose tissue
|
| 7098 |
TNF
|
|
decreases_expression of
|
PPARG
|
in adipose tissue
|
| 7099 |
TNF
|
|
decreases_expression of
|
RXR
|
in adipose tissue
|
| 7272 |
TNF
|
|
increases_activity of
|
I-kappa-B kinase complex
|
|
| 7281 |
adipose tissue macrophage
|
|
increases_quantity of
|
TNF
|
in adipose tissue
|
| 7327 |
TLR4
|
|
increases_expression of
|
TNF
|
|
|
18053812
|
Diabetes mellitus, type II
Obesity
Insulin resistance
|
|
1,100
|
| 6993 |
Parkinson disease
|
|
increases_quantity of
|
TNF
|
in brain
|
|
20423606
|
Parkinson disease
|
|
1,102
|
| 7026 |
Alzheimer disease
|
|
increases_quantity of
|
TNF
|
in PBMCs from AD patients compared to PBMCs in healthy controls
|
|
20462385
|
Alzheimer disease
|
CIDeRplus